Drug Approval | May 30, 2026
FDA delays AstraZeneca decision on camizestrant as regulators seek more data
The filing is backed by results from the pivotal SERENA-6 Phase III trial
The filing is backed by results from the pivotal SERENA-6 Phase III trial
The Hyderabad Public School Society celebrates Dr Rao’s journey from HPS Ramanthapur to becoming one of India's leading medical professionals
Solvay will fund Pantys-led initiatives targeting vulnerable communities through product donations and menstrual health education programs
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
The device screens for conditions like diabetic retinopathy, glaucoma, age-related macular degeneration, cataract and refractive error, in under ten minutes per patient
For the full year, standalone gross revenue crossed Rs. 1,700 crore
Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress
Company launches clinical study of AI-designed oral formulation following MHRA approval, marking a major milestone in AI-driven drug development.
Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
Subscribe To Our Newsletter & Stay Updated
